About
CatalYm

Pioneers in neutralizing GDF-15
to overcome cancer therapy resistance

CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors. GDF-15, a local immunosuppressant expressed during cellular stress responses, is hijacked by cancer cells to evade immune system attacks. Visugromab, CatalYm’s lead antibody, has demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1. CatalYm is now advancing into Phase 2b studies to confirm visugromab as a new class of cancer immunotherapy in a broad range of anti-cancer regimens, also in earlier treatment lines.

Our Science

Our Pipeline

Latest News

Leadership Team

+
Interim Chief Executive Officer (CEO)
Chief Financial Officer (CFO)
+
Chief Scientific Officer (CSO)
+
Chief Medical Officer (CMO)
+
SVP of Program Development

Board of Directors

Interim Chairman

Jon is a Managing Partner at Bioqube Ventures. Previously, he served as Managing Director at Red Tree Venture Capital and was part of the founding team at Medicxi where he was a partner in the London (...)

Read more
Board member

Colleen Cuffaro is a partner on Canaan’s healthcare investment team.  She serves on the boards of Arrakis Therapeutics, Alphina Therapeutics, RADD Pharmaceuticals and is a board observer at Agomab (...)

Read more
Independent board member

Hans van Eenennaam is CEO and founder of IMMIOS and Chief Scientific Officer at Sairopa. Previously, he served as Chief Scientific Officer of AIMM Therapeutics and as Executive Vice President of Antibody (...)

Read more
Board member

Jonathan is a Partner at Brandon Capital where he heads European operations and serves on the boards of Pheon Therapeutics, Myricx Bio, Astronautx and NRG Therapeutics. Previously, he was Managing Director (...)

Read more

Otello founded Omega Funds in 2004 and leads the firm’s investor relations and strategic initiatives. He is a member of the firm’s investment committee and is also heavily involved in a number of (...)

Read more
Board member

Rachel Mears is a Partner at Jeito Capital and has over 20 years of transactional, operational, and legal experience in biotechnology and pharma companies.

She led Strategy and International (...)

Read more
Board member

Rogier Rooswinkel is General Partner at Forbion where he is responsible for evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology. Prior to (...)

Read more
Independent board member

Roy Baynes received his MB, BCh (Bachelor of Medicine and Surgery) from the University of Witwatersrand, where he also received an MMed (specialist registration) and completed a PhD exploring mechanisms (...)

Read more

Our Investors

Our mission is supported by a syndicate
of renowned life science investors

WordPress Cookie Notice by Real Cookie Banner